Analysts think INDP stock price could increase by 734%
Nov 27, 2024, 12:26 PM
-18.27%
What does INDP do
Indaptus Therapeutics, a preclinical biotechnology company based in New York City, focuses on multi-targeted immune system activation using a Decoy platform for anti-tumor and anti-viral responses. Its lead candidate, Decoy20, shows promise against chronic HBV and HIV infections.
4 analysts think INDP stock price will increase by 733.65%. The current median analyst target is $8.67 compared to a current stock price of $1.04. The lowest analysts target is $5.05 and the highest analyst target is $12.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
